CA2296815A1 - Serie de 64 proteines humaines secretees - Google Patents
Serie de 64 proteines humaines secretees Download PDFInfo
- Publication number
- CA2296815A1 CA2296815A1 CA002296815A CA2296815A CA2296815A1 CA 2296815 A1 CA2296815 A1 CA 2296815A1 CA 002296815 A CA002296815 A CA 002296815A CA 2296815 A CA2296815 A CA 2296815A CA 2296815 A1 CA2296815 A1 CA 2296815A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- gene
- tissues
- sequence
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 701
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 272
- 241000282414 Homo sapiens Species 0.000 title abstract description 24
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 19
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 16
- 239000013598 vector Substances 0.000 claims abstract description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 373
- 108091033319 polynucleotide Proteins 0.000 claims description 373
- 239000002157 polynucleotide Substances 0.000 claims description 372
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 351
- 229920001184 polypeptide Polymers 0.000 claims description 348
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 348
- 230000014509 gene expression Effects 0.000 claims description 233
- 125000003729 nucleotide group Chemical group 0.000 claims description 167
- 239000000047 product Substances 0.000 claims description 105
- 239000002773 nucleotide Substances 0.000 claims description 102
- 239000012472 biological sample Substances 0.000 claims description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 41
- 239000002299 complementary DNA Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 21
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 4
- 238000004166 bioassay Methods 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims 8
- 238000012258 culturing Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 689
- 210000004027 cell Anatomy 0.000 description 400
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 350
- 208000035475 disorder Diseases 0.000 description 276
- 235000018102 proteins Nutrition 0.000 description 262
- 239000000523 sample Substances 0.000 description 133
- 210000001124 body fluid Anatomy 0.000 description 127
- 238000003745 diagnosis Methods 0.000 description 123
- 238000011282 treatment Methods 0.000 description 97
- 201000010099 disease Diseases 0.000 description 74
- 238000009826 distribution Methods 0.000 description 69
- 239000003153 chemical reaction reagent Substances 0.000 description 68
- 206010028980 Neoplasm Diseases 0.000 description 66
- 230000001900 immune effect Effects 0.000 description 65
- 239000012530 fluid Substances 0.000 description 64
- 210000002381 plasma Anatomy 0.000 description 64
- 210000002966 serum Anatomy 0.000 description 64
- 210000001179 synovial fluid Anatomy 0.000 description 64
- 210000002700 urine Anatomy 0.000 description 64
- 210000000987 immune system Anatomy 0.000 description 60
- 238000009169 immunotherapy Methods 0.000 description 47
- 230000004069 differentiation Effects 0.000 description 45
- 239000000439 tumor marker Substances 0.000 description 41
- 210000002751 lymph Anatomy 0.000 description 38
- 208000026278 immune system disease Diseases 0.000 description 37
- 210000000130 stem cell Anatomy 0.000 description 33
- 230000035755 proliferation Effects 0.000 description 32
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 238000001514 detection method Methods 0.000 description 27
- 230000001850 reproductive effect Effects 0.000 description 24
- 230000001605 fetal effect Effects 0.000 description 23
- 210000000481 breast Anatomy 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 20
- 230000014616 translation Effects 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 238000013519 translation Methods 0.000 description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 210000000349 chromosome Anatomy 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 206010003246 arthritis Diseases 0.000 description 16
- 210000004381 amniotic fluid Anatomy 0.000 description 15
- 208000032839 leukemia Diseases 0.000 description 15
- 239000003550 marker Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 210000001550 testis Anatomy 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 230000033228 biological regulation Effects 0.000 description 14
- 208000012239 Developmental disease Diseases 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 230000003394 haemopoietic effect Effects 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 230000001537 neural effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 108700026244 Open Reading Frames Proteins 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 208000019423 liver disease Diseases 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 208000006673 asthma Diseases 0.000 description 10
- 230000036737 immune function Effects 0.000 description 10
- 208000030159 metabolic disease Diseases 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 201000000980 schizophrenia Diseases 0.000 description 10
- 230000008733 trauma Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 9
- 208000012902 Nervous system disease Diseases 0.000 description 9
- 208000025966 Neurological disease Diseases 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 9
- 230000005856 abnormality Effects 0.000 description 9
- 230000030741 antigen processing and presentation Effects 0.000 description 9
- 210000000748 cardiovascular system Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 208000003669 immune deficiency disease Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 210000002826 placenta Anatomy 0.000 description 9
- 230000024833 regulation of cytokine production Effects 0.000 description 9
- 210000004994 reproductive system Anatomy 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 206010003805 Autism Diseases 0.000 description 8
- 208000020706 Autistic disease Diseases 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 8
- 208000023105 Huntington disease Diseases 0.000 description 8
- 208000029462 Immunodeficiency disease Diseases 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 206010026749 Mania Diseases 0.000 description 8
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 8
- 206010033864 Paranoia Diseases 0.000 description 8
- 208000027099 Paranoid disease Diseases 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 208000028017 Psychotic disease Diseases 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 8
- 208000000323 Tourette Syndrome Diseases 0.000 description 8
- 208000016620 Tourette disease Diseases 0.000 description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 210000004996 female reproductive system Anatomy 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- 201000003723 learning disability Diseases 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 208000019906 panic disease Diseases 0.000 description 8
- 230000008447 perception Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 230000007958 sleep Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 7
- 206010000496 acne Diseases 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 235000020256 human milk Nutrition 0.000 description 7
- 210000004251 human milk Anatomy 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000007813 immunodeficiency Effects 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 230000009547 development abnormality Effects 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 208000006359 hepatoblastoma Diseases 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- 208000017701 Endocrine disease Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010039710 Scleroderma Diseases 0.000 description 4
- 208000000491 Tendinopathy Diseases 0.000 description 4
- 206010043255 Tendonitis Diseases 0.000 description 4
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 4
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000002873 global sequence alignment Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000000777 hematopoietic system Anatomy 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108091008819 oncoproteins Proteins 0.000 description 4
- 210000004560 pineal gland Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000007261 regionalization Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 201000004415 tendinitis Diseases 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010033661 Pancytopenia Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 208000017504 atelosteogenesis type II Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000017568 chondrodysplasia Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 238000011124 ex vivo culture Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 230000037451 immune surveillance Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000002364 leukopenia Diseases 0.000 description 3
- 231100001022 leukopenia Toxicity 0.000 description 3
- 208000015625 metaphyseal chondrodysplasia Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 208000018360 neuromuscular disease Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 201000003437 pleural cancer Diseases 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 210000001044 sensory neuron Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 2
- 108010069271 FKBP-13 Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000027472 Galactosemias Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000000203 Hyaline Membrane Disease Diseases 0.000 description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 description 2
- 206010021067 Hypopituitarism Diseases 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
- 108050009313 NADH:ubiquinone oxidoreductases Proteins 0.000 description 2
- 102000002023 NADH:ubiquinone oxidoreductases Human genes 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108010067035 Pancrelipase Proteins 0.000 description 2
- 102100026408 Peptidyl-prolyl cis-trans isomerase FKBP2 Human genes 0.000 description 2
- 241000097929 Porphyria Species 0.000 description 2
- 208000010642 Porphyrias Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 108090001027 Troponin Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001767 chemoprotection Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 210000004879 pulmonary tissue Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100228206 Caenorhabditis elegans gly-6 gene Proteins 0.000 description 1
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010067248 Congenital naevus Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100022874 Dexamethasone-induced Ras-related protein 1 Human genes 0.000 description 1
- 241000168726 Dictyostelium discoideum Species 0.000 description 1
- 101001130230 Dictyostelium discoideum Ras-related protein Rab-21 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108091011114 FK506 binding proteins Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101100060915 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) comF gene Proteins 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 230000010556 Heparin Binding Activity Effects 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101710135007 Histone-like protein p6 Proteins 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 108050009606 Homeobox domains Proteins 0.000 description 1
- 102000001420 Homeobox domains Human genes 0.000 description 1
- 101000690251 Homo sapiens Aldo-keto reductase family 1 member D1 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 201000009139 Mongolian Spot Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102100040600 Myotubularin-related protein 3 Human genes 0.000 description 1
- 101710147291 Myotubularin-related protein 3 Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 101100326804 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-2 gene Proteins 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048211 Xanthelasma Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 230000030400 head development Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000004169 miliaria rubra Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000020043 port wine Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 208000011865 skeletal system disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010030159 thrombin receptor peptide 14 Proteins 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une série de 64 nouvelles protéines humaines sécrétées ainsi que des acides nucléiques isolés contenant les régions de codage des gènes codant lesdites protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison permettant d'élaborer des protéines humaines sécrétées. L'invention concerne aussi des procédés diagnostiques et thérapeutiques utiles pour le diagnostic et le traitement de troubles liés à ces nouvelles protéines humaines sécrétées.
Applications Claiming Priority (41)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5287397P | 1997-07-16 | 1997-07-16 | |
| US5287597P | 1997-07-16 | 1997-07-16 | |
| US5287497P | 1997-07-16 | 1997-07-16 | |
| US5266197P | 1997-07-16 | 1997-07-16 | |
| US5287197P | 1997-07-16 | 1997-07-16 | |
| US5287297P | 1997-07-16 | 1997-07-16 | |
| US5287097P | 1997-07-16 | 1997-07-16 | |
| US60/052,872 | 1997-07-16 | ||
| US60/052,870 | 1997-07-16 | ||
| US60/052,873 | 1997-07-16 | ||
| US60/052,875 | 1997-07-16 | ||
| US60/052,661 | 1997-07-16 | ||
| US60/052,874 | 1997-07-16 | ||
| US60/052,871 | 1997-07-16 | ||
| US5344197P | 1997-07-22 | 1997-07-22 | |
| US5344097P | 1997-07-22 | 1997-07-22 | |
| US5344297P | 1997-07-22 | 1997-07-22 | |
| US60/053,442 | 1997-07-22 | ||
| US60/053,440 | 1997-07-22 | ||
| US60/053,441 | 1997-07-22 | ||
| US5594697P | 1997-08-18 | 1997-08-18 | |
| US5635997P | 1997-08-18 | 1997-08-18 | |
| US5598597P | 1997-08-18 | 1997-08-18 | |
| US5595297P | 1997-08-18 | 1997-08-18 | |
| US5572497P | 1997-08-18 | 1997-08-18 | |
| US5568397P | 1997-08-18 | 1997-08-18 | |
| US5636197P | 1997-08-18 | 1997-08-18 | |
| US5572697P | 1997-08-18 | 1997-08-18 | |
| US5572597P | 1997-08-18 | 1997-08-18 | |
| US5598997P | 1997-08-18 | 1997-08-18 | |
| US60/055,989 | 1997-08-18 | ||
| US60/055,724 | 1997-08-18 | ||
| US60/056,359 | 1997-08-18 | ||
| US60/055,952 | 1997-08-18 | ||
| US60/055,985 | 1997-08-18 | ||
| US60/055,726 | 1997-08-18 | ||
| US60/055,683 | 1997-08-18 | ||
| US60/055,946 | 1997-08-18 | ||
| US60/056,361 | 1997-08-18 | ||
| US60/055,725 | 1997-08-18 | ||
| PCT/US1998/014613 WO1999003990A1 (fr) | 1997-07-16 | 1998-07-15 | Serie de 64 proteines humaines secretees |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2296815A1 true CA2296815A1 (fr) | 1999-01-28 |
Family
ID=27586422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002296815A Abandoned CA2296815A1 (fr) | 1997-07-16 | 1998-07-15 | Serie de 64 proteines humaines secretees |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1027430A4 (fr) |
| JP (1) | JP2003524366A (fr) |
| AU (1) | AU8404598A (fr) |
| CA (1) | CA2296815A1 (fr) |
| WO (1) | WO1999003990A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| US7258973B2 (en) * | 1998-08-31 | 2007-08-21 | Mayo Foundation For Medical Education & Research | Method for detecting a differentially expressed sequence |
| US6344541B1 (en) | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
| EP1144603A3 (fr) * | 1999-01-22 | 2002-02-06 | Memorec Medical Molecular Research Cologne Stoffel GmbH | Protease |
| JP2002540763A (ja) * | 1999-02-10 | 2002-12-03 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ３３個のヒト分泌タンパク質 |
| WO2000065067A2 (fr) * | 1999-04-23 | 2000-11-02 | University Of Washington | Polynucleotides, polypeptides specifiques a la prostate, et leurs procedes d'utilisation |
| AU5316800A (en) * | 1999-08-05 | 2001-03-05 | Incyte Genomics, Inc. | Secretory molecules |
| KR100543857B1 (ko) * | 1999-09-01 | 2006-01-23 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 |
| AU7589800A (en) * | 1999-09-28 | 2001-04-30 | Incyte Genomics, Inc. | Secretory molecules |
| WO2001098483A1 (fr) * | 2000-06-22 | 2001-12-27 | Zoegene Corporation | Gene codant une nouvelle proteine de type protocadherine |
| EP2280030A3 (fr) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers |
| US7927597B2 (en) | 2001-04-10 | 2011-04-19 | Agensys, Inc. | Methods to inhibit cell growth |
| US7709611B2 (en) | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
| WO2006015497A1 (fr) * | 2004-08-13 | 2006-02-16 | Val-Chum, S.E.C. | Procedes d'utilisation d'une proteine dkk1, de polypeptides immunogenes de ladite proteine, d'acides nucleiques codant la proteine dkk1 ou des polypeptides, ou de ligands de ladite proteine, pour detecter des tumeurs et pour eliciter une reponse immunitaire contre des tumeurs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024474A1 (fr) * | 1994-03-10 | 1995-09-14 | Human Genome Sciences, Inc. | Proteine 10 osseuse morphogenique |
-
1998
- 1998-07-15 JP JP2000503196A patent/JP2003524366A/ja not_active Withdrawn
- 1998-07-15 AU AU84045/98A patent/AU8404598A/en not_active Abandoned
- 1998-07-15 WO PCT/US1998/014613 patent/WO1999003990A1/fr not_active Application Discontinuation
- 1998-07-15 CA CA002296815A patent/CA2296815A1/fr not_active Abandoned
- 1998-07-15 EP EP98934551A patent/EP1027430A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1027430A4 (fr) | 2001-09-19 |
| EP1027430A1 (fr) | 2000-08-16 |
| JP2003524366A (ja) | 2003-08-19 |
| WO1999003990A1 (fr) | 1999-01-28 |
| AU8404598A (en) | 1999-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6420526B1 (en) | 186 human secreted proteins | |
| US20050089911A1 (en) | 87 human secreted proteins | |
| US20050079537A1 (en) | 44 human secreted proteins | |
| CA2295474A1 (fr) | 123 proteines humaines secretees | |
| WO1999031117A1 (fr) | 110 proteines secretees humaines | |
| US20060188962A1 (en) | 19 human secreted proteins | |
| US6525174B1 (en) | Precerebellin-like protein | |
| US6881823B2 (en) | Human protein HFXJW48 | |
| CA2294526A1 (fr) | 86 proteines secretees humaines | |
| CA2317702A1 (fr) | 36 proteines humaines secretees | |
| EP1019091A1 (fr) | 50 proteines secretees d'origine humaine | |
| CA2296815A1 (fr) | Serie de 64 proteines humaines secretees | |
| EP1032838A1 (fr) | 125 proteines secretees humaines | |
| CA2305690A1 (fr) | 53 proteines secretees humaines | |
| WO1999022243A1 (fr) | 148 proteines humaines secretees | |
| US20010016647A1 (en) | 29 human secreted proteins | |
| CA2298852A1 (fr) | 83 proteines humaines secretees | |
| CA2305685A1 (fr) | 101 proteines humaines secretees | |
| CA2321970A1 (fr) | Proteines secretees par l'homme | |
| US20050214844A1 (en) | 86 human secreted proteins | |
| EP1439189A2 (fr) | 86 protéines humainess sécrétées | |
| EP1557425A2 (fr) | Protéine humaine sécrétée | |
| EP1346999A2 (fr) | Protéine humaine secrétée | |
| EP1464653A1 (fr) | Protéine humaine sécrétée | |
| EP1445316A1 (fr) | Nouvelle protéine secretée |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |